Tilray Brands, Inc. (TLRY) stock
TLRYNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 8, 2026Score 11/3086% below fair value
$2.43−0.06 (-2.41%)
Close on Nov 13, 2026Market cap $359.12MP/E –Yield –
Tilray Brands r&d expenses
Research and development expenses are spending on new products and technology.
Tilray Brands's R&D Expenses for the twelve months ending Aug 31, 2026 was $409.00K, up 85.9% year over year. For fiscal 2026 it was $361.00K, up 27.1% from the year before. The highest annual figure on record is $9.17M in fiscal 2019.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | May 31, 2026 | $361.00K | +27.1% |
| FY2025 | May 31, 2025 | $284.00K | -55.3% |
| FY2024 | May 31, 2024 | $635.00K | -6.9% |
| FY2023 | May 31, 2023 | $682.00K | -55.1% |
| FY2022 | May 31, 2022 | $1.52M | -83.4% |
| FY2019 | Dec 31, 2019 | $9.17M | +56.4% |
| FY2018 | Dec 31, 2018 | $5.86M | +84.9% |
| FY2017 | Dec 31, 2017 | $3.17M | +179.1% |
| FY2016 | Dec 31, 2016 | $1.14M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | $89.00K | +117.1% |
| Q4 FY2026CQ2 2026 | May 31, 2026 | $180.00K | +429.4% |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | $62.00K | -27.1% |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | $78.00K | +30.0% |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | $41.00K | -61.0% |
| Q4 FY2025CQ2 2025 | May 31, 2025 | $34.00K | -91.4% |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | $85.00K | -19.8% |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | $60.00K | +7.1% |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | $105.00K | +32.9% |
| Q4 FY2024CQ2 2024 | May 31, 2024 | $394.00K | +118.9% |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | $106.00K | -38.0% |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | $56.00K | -66.1% |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | $79.00K | -52.4% |
| Q4 FY2023CQ2 2023 | May 31, 2023 | $180.00K | +233.3% |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | $171.00K | +4.3% |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | $165.00K | -68.0% |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | $166.00K | -78.9% |
| Q4 FY2022CQ2 2022 | May 31, 2022 | $54.00K | -98.7% |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | $164.00K | -92.9% |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | $515.00K | -66.3% |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | $785.00K | -25.1% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $4.28M | +24.2% |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | $2.32M | +188.7% |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | $1.53M | +139.1% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | $1.05M | +7.5% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $3.45M | +365.9% |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | $802.00K | +10.0% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $639.00K | -38.6% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $975.00K | – |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | $740.00K | – |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $729.00K | – |
| Q2 FY2017CQ2 2017 | Jun 30, 2017 | $1.04M | – |
See a number that looks wrong?